# Arbutus Reports Second Quarter 2025 Financial Results and Provides Corporate Update
Canonical URL: https://biopharmsignal.com/news/ABUS/arbutus-reports-second-quarter-2025-financial-results-and-provides-corporate-update
Ticker: ABUS
Company: Arbutus
Source: Arbutus
Published: 2025-08-06 11:30 EST
Original Source URL: https://investor.arbutusbio.com
## Summary

Q2 total revenue of $10.7M includes previously-deferred revenue following reacquisition of Greater China rights to imdusiran Dr. Roger Sawhney joins the Arbutus Board of Directors following resignation of Anuj Hasija Dr. Harry Janssen joins the Arbutus Scientific Advisory Board Strong financial

## Article Body
Q2 total revenue of $10.7M includes previously-deferred revenue following reacquisition of Greater China rights to imdusiran Dr. Roger Sawhney joins the Arbutus Board of Directors following resignation of Anuj Hasija Dr. Harry Janssen joins the Arbutus Scientific Advisory Board Strong financial
## Recent Company News
- 2026-07-16 11:30 EST — [Arbutus Initiates International Patent Infringement Enforcement Actions Against Pfizer and BioNTech, Receives First Payment From Moderna Settlement Agreement and Announces Intent to Return Capital to Shareholders](https://biopharmsignal.com/news/ABUS/arbutus-initiates-international-patent-infringement-enforcement-actions-against--c6198417) — Source: Arbutus
- 2026-05-13 11:30 EST — [Arbutus Reports First Quarter 2026 Financial Results and Provides Corporate Update](https://biopharmsignal.com/news/ABUS/arbutus-reports-first-quarter-2026-financial-results-and-provides-corporate-update) — Source: Arbutus
- 2026-04-15 11:30 EST — [Arbutus Receives U.S. FDA Fast Track Designation for Imdusiran for the Treatment of Chronic Hepatitis B](https://biopharmsignal.com/news/ABUS/arbutus-receives-u-s-fda-fast-track-designation-for-imdusiran-for-the-treatment-of-chronic-hepatitis-b) — Source: Arbutus
- 2026-03-23 11:30 EST — [Arbutus Reports Fourth Quarter and Year End 2025 Financial Results and Provides Corporate Update](https://biopharmsignal.com/news/ABUS/arbutus-reports-fourth-quarter-and-year-end-2025-financial-results-and-provides-corporate-update) — Source: Arbutus
- 2026-03-03 21:15 EST — [Genevant Sciences and Arbutus Biopharma Announce $2.25 Billion Global Settlement With Moderna](https://biopharmsignal.com/news/ABUS/genevant-sciences-and-arbutus-biopharma-announce-2-25-billion-global-settlement-with-moderna) — Source: Arbutus
## Related News
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)
- 2026-07-29 12:25 EST — ICCM — [IceCure: SIO Petitions NCCN to Include Cryoablation in Breast Cancer Treatment Guidelines, Citing IceCure's FDA Clearance  of ProSense®](https://biopharmsignal.com/news/ICCM/icecure-sio-petitions-nccn-to-include-cryoablation-in-breast-cancer-treatment-gu-bec46cd3)